We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MetLife (MET) Reports Q1 Earnings: What Key Metrics Have to Say
Read MoreHide Full Article
MetLife (MET - Free Report) reported $17.02 billion in revenue for the quarter ended March 2024, representing a year-over-year increase of 5.5%. EPS of $1.83 for the same period compares to $1.52 a year ago.
The reported revenue represents a surprise of -3.81% over the Zacks Consensus Estimate of $17.69 billion. With the consensus EPS estimate being $1.83, the company has not delivered EPS surprise.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how MetLife performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Total Adjusted Revenue- Latin America: $1.88 billion versus the three-analyst average estimate of $1.95 billion. The reported number represents a year-over-year change of +7.5%.
Adjusted Revenue- Corporate & other- Premiums: $6 million versus the three-analyst average estimate of $16.40 million. The reported number represents a year-over-year change of -62.5%.
Total Adjusted Revenue- EMEA: $674 million versus the three-analyst average estimate of $650.81 million. The reported number represents a year-over-year change of +7.7%.
Total Adjusted Revenue- Asia: $2.85 billion versus $2.86 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6.6% change.
Revenue- Premiums: $10.05 billion versus $10.88 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +4.8% change.
Revenue- Other Revenues: $674 million versus the five-analyst average estimate of $633.59 million. The reported number represents a year-over-year change of +5.5%.
Revenue- Universal life and investment-type product policy fees: $1.25 billion compared to the $1.33 billion average estimate based on five analysts. The reported number represents a change of -3.2% year over year.
Revenue- Net investment income: $5.44 billion compared to the $4.93 billion average estimate based on five analysts. The reported number represents a change of +17% year over year.
Adjusted Revenue- Retirement & Income Solutions- Premiums: $675 million versus $1.64 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +34.7% change.
Adjusted Revenue- Retirement & Income Solutions- Universal life and investment-type product policy fees: $75 million compared to the $86.40 million average estimate based on three analysts. The reported number represents a change of -5.1% year over year.
Adjusted Revenue- Retirement & Income Solutions- Net investment income: $2.09 billion versus the three-analyst average estimate of $1.91 billion. The reported number represents a year-over-year change of +15.2%.
Adjusted Revenue- Retirement & Income Solutions- Other Revenues: $63 million versus $68.46 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -7.4% change.
Shares of MetLife have returned -2.9% over the past month versus the Zacks S&P 500 composite's -4.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
MetLife (MET) Reports Q1 Earnings: What Key Metrics Have to Say
MetLife (MET - Free Report) reported $17.02 billion in revenue for the quarter ended March 2024, representing a year-over-year increase of 5.5%. EPS of $1.83 for the same period compares to $1.52 a year ago.
The reported revenue represents a surprise of -3.81% over the Zacks Consensus Estimate of $17.69 billion. With the consensus EPS estimate being $1.83, the company has not delivered EPS surprise.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how MetLife performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Total Adjusted Revenue- Latin America: $1.88 billion versus the three-analyst average estimate of $1.95 billion. The reported number represents a year-over-year change of +7.5%.
- Adjusted Revenue- Corporate & other- Premiums: $6 million versus the three-analyst average estimate of $16.40 million. The reported number represents a year-over-year change of -62.5%.
- Total Adjusted Revenue- EMEA: $674 million versus the three-analyst average estimate of $650.81 million. The reported number represents a year-over-year change of +7.7%.
- Total Adjusted Revenue- Asia: $2.85 billion versus $2.86 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6.6% change.
- Revenue- Premiums: $10.05 billion versus $10.88 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +4.8% change.
- Revenue- Other Revenues: $674 million versus the five-analyst average estimate of $633.59 million. The reported number represents a year-over-year change of +5.5%.
- Revenue- Universal life and investment-type product policy fees: $1.25 billion compared to the $1.33 billion average estimate based on five analysts. The reported number represents a change of -3.2% year over year.
- Revenue- Net investment income: $5.44 billion compared to the $4.93 billion average estimate based on five analysts. The reported number represents a change of +17% year over year.
- Adjusted Revenue- Retirement & Income Solutions- Premiums: $675 million versus $1.64 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +34.7% change.
- Adjusted Revenue- Retirement & Income Solutions- Universal life and investment-type product policy fees: $75 million compared to the $86.40 million average estimate based on three analysts. The reported number represents a change of -5.1% year over year.
- Adjusted Revenue- Retirement & Income Solutions- Net investment income: $2.09 billion versus the three-analyst average estimate of $1.91 billion. The reported number represents a year-over-year change of +15.2%.
- Adjusted Revenue- Retirement & Income Solutions- Other Revenues: $63 million versus $68.46 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -7.4% change.
View all Key Company Metrics for MetLife here>>>Shares of MetLife have returned -2.9% over the past month versus the Zacks S&P 500 composite's -4.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.